{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:16:52Z","timestamp":1790709412630,"version":"4.1.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Cystic fibrosis (CF) transmembrane conductance regulator protein (CFTR) modulators have significantly improved health outcomes in patients with cystic fibrosis (pwCF). However, in Turkey, access is limited due to lack of insurance coverage, and treatment is only granted in 3-month periods via court rulings. This study aimed to compare clinical outcomes between patients receiving continuous vs. intermittent modulator therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In this retrospective multicenter study, data from 229 CF patients across 14 centers in Turkey who received highly effective modulator therapy (HEMT) for at least six months were analyzed. Patients were grouped based on whether they received treatment continuously (Group 1) or with interruptions (Group 2). Changes in percent predicted forced expiratory volume in one second (ppFEV\u2081) and body mass index (BMI) were evaluated at baseline, 3 months, and 6 months. For Group 2, ppFEV\u2081 was also assessed during interruption periods.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 229 patients, 38.4% received continuous treatment while 61.5% experienced treatment interruptions. Both groups showed significant improvements in ppFEV\u2081 over six months (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001). However, Group 2 experienced a significant decline during interruption periods (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.001), followed by recovery upon reinitiation. BMI also increased significantly in both groups (<jats:italic>p<\/jats:italic>\u2009&amp;lt;\u20090.05). Patients with baseline ppFEV\u2081\u2009&amp;lt;\u200970% showed greater improvement compared to those with milder disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Short-term clinical outcomes in ppFEV\u2081 and BMI were similar between continuous and intermittent treatment. However, treatment interruptions may reduce cumulative benefits, potentially impacting long-term outcomes. Ensuring uninterrupted access to HEMT is essential, especially in low- and middle-income countries<jats:bold>.<\/jats:bold><\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2025.1659633","type":"journal-article","created":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T04:17:36Z","timestamp":1760329056000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of interrupted and continuous modulator therapy in cystic fibrosis: a real life experience in Turkey"],"prefix":"10.3389","volume":"13","author":[{"given":"Almala Pinar","family":"Ergenekon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merve","family":"Selcuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gokcen","family":"Unal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gamzegul","family":"Gozen Bayramo\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cansu","family":"Altuntas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Kose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdurrahman Erdem","family":"Basaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinem","family":"Can Oksay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salih","family":"Uytun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sedat","family":"Oktem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep Seda","family":"Uyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakup","family":"Canitez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esen","family":"Demir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Velat","family":"Sen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veysel","family":"Karakulak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ela","family":"Erdem Eralp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bulent","family":"Karadag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fazilet","family":"Karakoc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevgi","family":"Pekcan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tugba","family":"Sismanlar Eyubo\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erkan","family":"Cak\u0131r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasemin","family":"Gokdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/S0140-6736(23)01609-4","article-title":"CFTR modulator therapy: transforming the landscape of clinical care in cystic fibrosis","volume":"402","author":"Taylor-Cousar","year":"2023","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"BSR20212006","DOI":"10.1042\/BSR20212006","article-title":"Molecular mechanisms of cystic fibrosis - how mutations lead to misfunction and guide therapy","volume":"42","author":"Farinha","year":"2022","journal-title":"Biosci Rep"},{"key":"B3","doi-asserted-by":"publisher","first-page":"102239","DOI":"10.1016\/j.coph.2022.102239","article-title":"Current state of CFTR modulators for treatment of cystic fibrosis","volume":"65","author":"Despotes","year":"2022","journal-title":"Curr Opin Pharmacol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s12931-023-02497-0","article-title":"The clinical impact of lumacaftor-ivacaftor on structural lung disease and lung function in children aged 6\u201311 with cystic fibrosis in a real-world setting","volume":"24","author":"McNally","year":"2023","journal-title":"Respir Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S2213-2600(20)30510-5","article-title":"Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study","volume":"9","author":"Flume","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1002\/ppul.26535","article-title":"Patients with cystic fibrosis who could not receive the CFTR modulator treatment: what did they lose in 1 year?","volume":"58","author":"Uytun","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.jcf.2023.03.002","article-title":"Real-world safety and effectiveness of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis: interim results of a long-term registry-based study","volume":"22","author":"Bower","year":"2023","journal-title":"J Cyst Fibros"},{"key":"B9","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1164\/rccm.202301-0084OC","article-title":"Phase 3 open-label clinical trial of elexacaftor\/tezacaftor\/ivacaftor in children aged 2\u20135 years with cystic fibrosis and at least one F508del allele","volume":"208","author":"Goralski","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"key":"B10","article-title":"CFTR2: Clinical and functional translation of CFTR","year":""},{"key":"B11","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.jcf.2024.05.006","article-title":"Impact of interruption of CFTR modulator therapies","volume":"23","author":"Capraz Yavuz","year":"2024","journal-title":"J Cyst Fibros"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2101499","DOI":"10.1183\/13993003.01499-2021","article-title":"ERS\/ATS technical standard on interpretive strategies for routine lung function tests","volume":"60","author":"Stanojevic","year":"2022","journal-title":"Eur Respir J"},{"key":"B13","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jpeds.2015.08.042","article-title":"Forced expiratory volume in 1 second variability helps identify patients with cystic fibrosis at risk of greater loss of lung function","volume":"169","author":"Morgan","year":"2016","journal-title":"J Pediatr"},{"key":"B14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S1569-1993(02)00141-8","article-title":"Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients","volume":"2","author":"Lee","year":"2003","journal-title":"J Cyst Fibros"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1056\/NEJMoa1807120","article-title":"VX-445-tezacaftor-ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles","volume":"379","author":"Keating","year":"2018","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e27390","DOI":"10.1002\/ppul.27390","article-title":"Respiratory outcomes of interrupted modulator therapies in children with cystic fibrosis","volume":"60","author":"Oztosun","year":"2025","journal-title":"Pediatr Pulmonol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3390\/nu15030479","article-title":"Nutritional care in children with cystic fibrosis","volume":"15","author":"Mariotti Zani","year":"2023","journal-title":"Nutrients"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.3390\/nu13061801","article-title":"Change in nutrient and dietary intake in European children with cystic fibrosis after a 6-month intervention with a self-management mHealth tool","volume":"13","author":"Calvo-Lerma","year":"2021","journal-title":"Nutrients"},{"key":"B20","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.jpeds.2008.07.011","article-title":"Improvements in lung function outcomes in children with cystic fibrosis are associated with better nutrition, fewer chronic pseudomonas aeruginosa infections, and dornase alfa use","volume":"153","author":"McPhail","year":"2008","journal-title":"J Pediatr"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1002\/ppul.26344","article-title":"Improvements in body mass index of children with cystic fibrosis following implementation of a standardized nutritional algorithm: a quality improvement project","volume":"58","author":"Gokdemir","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"554","DOI":"10.3390\/children10030554","article-title":"Efficacy and safety of elexacaftor-tezacaftor-ivacaftor in the treatment of cystic fibrosis: a systematic review","volume":"10","author":"Kapouni","year":"2023","journal-title":"Children (Basel)"},{"key":"B23","article-title":"ECFS 2023 patient registry annual report","year":"2023"},{"key":"B24","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jcf.2020.07.017","article-title":"Projecting the impact of delayed access to elexacaftor\/tezacaftor\/ivacaftor for people with cystic fibrosis","volume":"20","author":"Stanojevic","year":"2021","journal-title":"J Cyst Fibros"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e71155","DOI":"10.1002\/ppul.71155","article-title":"Impact of modulator therapy on the chronic colonization of lower respiratory tract pathogens in children: data from cystic fibrosis registry of Turkey","volume":"60","author":"Sunman","year":"2025","journal-title":"Pediatr Pulmonol"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1659633\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T04:17:37Z","timestamp":1760329057000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2025.1659633\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,13]]},"references-count":25,"alternative-id":["10.3389\/fped.2025.1659633"],"URL":"https:\/\/doi.org\/10.3389\/fped.2025.1659633","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,13]]},"article-number":"1659633"}}